| Literature DB >> 28351978 |
Takeharu Minamitani1, Yijie Ma2,3, Hufeng Zhou2,3, Hiroshi Kida4, Chao-Yuan Tsai5, Masanori Obana6, Daisuke Okuzaki7, Yasushi Fujio6, Atsushi Kumanogoh4,8, Bo Zhao2, Hitoshi Kikutani5, Elliott Kieff9,3, Benjamin E Gewurz9, Teruhito Yasui10.
Abstract
Epstein-Barr virus (EBV) is a major cause of immunosuppression-related B-cell lymphomas and Hodgkin lymphoma (HL). In these malignancies, EBV latent membrane protein 1 (LMP1) and LMP2A provide infected B cells with surrogate CD40 and B-cell receptor growth and survival signals. To gain insights into their synergistic in vivo roles in germinal center (GC) B cells, from which most EBV-driven lymphomas arise, we generated a mouse model with conditional GC B-cell LMP1 and LMP2A coexpression. LMP1 and LMP2A had limited effects in immunocompetent mice. However, upon T- and NK-cell depletion, LMP1/2A caused massive plasmablast outgrowth, organ damage, and death. RNA-sequencing analyses identified EBV oncoprotein effects on GC B-cell target genes, including up-regulation of multiple proinflammatory chemokines and master regulators of plasma cell differentiation. LMP1/2A coexpression also up-regulated key HL markers, including CD30 and mixed hematopoietic lineage markers. Collectively, our results highlight synergistic EBV membrane oncoprotein effects on GC B cells and provide a model for studies of their roles in immunosuppression-related lymphoproliferative diseases.Entities:
Keywords: Epstein–Barr virus; LMP1; LMP2A; plasmablast; posttransplant lymphoproliferative disorder
Mesh:
Substances:
Year: 2017 PMID: 28351978 PMCID: PMC5422827 DOI: 10.1073/pnas.1701836114
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205